GT Biopharma Inc
Change company Symbol lookup
Select an option...
GTBP GT Biopharma Inc
UNH UnitedHealth Group Inc
BAC Bank of America Corp
WSO Watsco Inc
LITB LightInTheBox Holding Co Ltd
CVCY Central Valley Community Bancorp
AFAQU AF Acquisition Corp
HCIIW Hudson Executive Investment Equity II Warrant Exp 31 Jan 2027 *W EXP 01/31/2027
MEDS TRxADE Health Inc
HCICW Hennessy Capital Investment V Equity Warrant Exp 15 Jan 2025 *W EXP 01/15/2025
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

Closing Price
$2.47
Day's Change
0.41 (19.90%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.48
Day's Low
2.10
Volume
(Average)
Volume:
171,097

10-day average volume:
170,736
171,097

Bad news for first-time buyers: Mortgage rates rise to pandemic-era high

3:01 pm ET January 22, 2022 (MarketWatch)
Print

By Jacob Passy

Home buyers today can expect to pay nearly $3,000 more a year to own a home than they would have a year ago

Mortgage rates rose to levels last seen in March 2020 as markets continued to price in expectations of an upcoming interest-rate increase from the Federal Reserve.

The 30-year fixed-rate mortgage averaged 3.56% for the week ending Jan. 20, up 11 basis points from the previous week, Freddie Mac (FMCC) reported Thursday. A year ago this time, the 30-year loan was averaging 2.77%

The 15-year fixed-rate mortgage, meanwhile, rose 17 basis points to an average of 2.79%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.6%, up three basis points from the previous week.

To put these numbers in perspective, the last time the rate on the benchmark 30-year loan was this high there had been just over 15,200 total COVID-19 cases in the U.S., according to data from the U.S. Centers for Disease Control and Prevention. Today, the total number of cases in the country has reached nearly 68.6 million, according to data from The New York Times.

Mortgage rates roughly track the direction of long-term bond yields, including the 10-year Treasury , which rose over the past week as data underscored the likelihood that the Federal Reserve will rollback its stimulus activities to curb high inflation.

"Economic indicators showed that labor markets remain tight, while consumer and producer prices continued to rise in December," said Paul Thomas, vice president of capital markets at Zillow (Z)(Z). "This data supports market expectations that the Federal Reserve will begin to move early in 2022 to address inflation, and potentially accelerate asset purchase tapering and balance sheet runoff."

For home buyers, this means that the monthly mortgage bill will be significantly higher than it was a year ago. According to an analysis from Realtor.com, at today's rates buyers can expect to pay $238 more per month on their mortgage than they would have if they had bought property at this time in 2021. That adds up to nearly $3,000 more per year, on account of the higher interest rate.

This will hit first-time buyers especially hard, said Realtor.com manager of economic research George Ratiu, and will shrink the budgets of what they can afford to buy -- at a time when home prices continue to rise.

-Jacob Passy

	

(END) Dow Jones Newswires

January 22, 2022 15:01 ET (20:01 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.